Term ends no later than Jul 25, 2032 · Medium confidence
20-year base term ends Jul 25, 2032
In force on USPTO's status record and by its fee record. A terminal disclaimer on file may shorten this term, possibly to a date already past; its reference document is unresolved, so the date above is an upper bound and no earlier date is guessed.
Held by AstraZeneca AB
Filed Jun 19, 2019 as application 16/445,709 · Granted Dec 8, 2020
Base term, 20 years from filing
Today
2012
2032
Clock starts
Jul 25, 2012
Jul 25, 2012
Ends no later than
Jul 25, 2032
Jul 25, 2032
Granted
Dec 8, 2020
Dec 8, 2020
base term
fee events
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
Unresolved
Terminal disclaimer
On file, reference document not resolved, so the date above is an upper bound. We do not guess the cap.
1 of 2
Maintenance fees paid
Two maintenance fees can end this term early, the ones due 3.5 and 7.5 years from grant; the third one's grace period runs past the term end. This counts the ones the record shows paid.
10
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is on file with no resolved reference, so no cap is applied and none is guessed. 1 of 2 maintenance fees is paid so far. Confidence: Medium. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jul 25, 2012, when application 13/557,871, the earliest non-provisional in its chain, was filed (this one was filed Jun 19, 2019) | Jul 25, 2032 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer on file (approved), reference document not resolved | no cap applied, and none guessed | Medium confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 1 of 2 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | no later than Jul 25, 2032 | Medium confidence |
This family
| US 8,946,235 | In force Aug 2032 | Aug 2032 |
| US 9,732,058 | In force Jul 2032 | Jul 2032 |
| US 10,017,493 | In force Jul 2032 | Jul 2032 |
| Application 15/991,578 | Abandoned not computed | not computed |
| US 10,858,336 | this patent no later than Jul 2032 | no later than Jul 2032 |
| US 11,524,951 | In force Jul 2032 | Jul 2032 |
| Application 17/979,342 | Abandoned not computed | not computed |
| Application 18/334,705 | Abandoned not computed | not computed |
8 of 10 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| May 22, 2020 Reel 52732, frame 352 | Butterworth, Sam; Finlay, Maurice Raymond Verschoyle; Ward, Richard Andrew; Redfearn, Heather Marie | AstraZeneca UK Limited | Assignment of Assignor's Interest |
| May 22, 2020 Reel 52732, frame 555 | Krishna Kadambar, Vasantha; Reddy C, Chandrasekhara; Murugan, Andiappan | AstraZeneca India Private Limited | Assignment of Assignor's Interest |
| May 22, 2020 Reel 52732, frame 612 | Chuaqui, Claudio Edmundo | AstraZeneca Pharmaceuticals LP | Assignment of Assignor's Interest |
| May 22, 2020 Reel 52732, frame 786 | AstraZeneca Pharmaceuticals LP | AstraZeneca UK Limited | Assignment of Assignor's Interest |
| May 22, 2020 Reel 52732, frame 935 | AstraZeneca India Private Limited | AstraZeneca AB | Assignment of Assignor's Interest |
| May 22, 2020 Reel 52733, frame 31 | AstraZeneca UK Limited | AstraZeneca AB | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Jul 2032
Term ends no later than Jul 25, 2032. Maintenance fees still fall due before then
Note
A terminal disclaimer is on file and its reference is not resolved. No cap is applied and none is guessed
Open question
A terminal disclaimer is on file (approved) and its reference document is not resolved. A disclaimer would cap the term earlier than Jul 25, 2032. We will not guess the cap.
Citations
0
later US patents cite this one
That is below the median of utility patents granted in 2020 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
This computed term ends no later than the date shown; an unresolved terminal disclaimer may end it earlier. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.